Cover Image
市場調查報告書

多發性硬化症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Multiple Sclerosis Forecast and Market Analysis to 2025

出版商 Datamonitor Healthcare 商品編碼 365215
出版日期 內容資訊 英文 780 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Multiple Sclerosis Forecast and Market Analysis to 2025
出版日期: 2017年11月24日 內容資訊: 英文 780 Pages
簡介

多發性硬化症的治療藥的市場可說是潛在市場規模很大,不過,正因為如此新加入企業和 (臨床實驗最後階段的) 開發平台候補藥等大量湧入市場,打算搶食現有企業/產品的市場佔有率,市場競爭變得非常激烈。

本報告提供多發性硬化症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,新藥上市的市場規模的變動預測,及現在、未來的代表性產品,疾病的各種類 (亞型) 的詳細情況,醫生面臨的各種問題等相關調查。

市場預測:多發性硬化症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Aubagio (teriflunomide)
  • Avonex (干擾素β-1a)
  • Betaseron/Betaferon (干擾素β-1b)
  • Copaxone (glatiramer acetate)
  • Extavia (干擾素β-1b)
  • Gilenya (Fingolimod)
  • Lemtrada (alemtuzumab)
  • Nerventra (laquinimod)
  • Ocrelizumab
  • ozanimod
  • Plegridy (PEG干擾素β-1a)
  • ponesimod
  • Rebif (干擾素β-1a)
  • siponimod
  • Tecfidera (富馬酸二甲酯)
  • Tysabri (natalizumab)
  • Zinbryta (daclizumab)
  • 一次調查技術

治療方法:多發性硬化症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 多發性硬化症相關的未滿足需求

流行病學:多發性硬化症

  • 摘要整理
  • 疾病的背景情況
  • 全球各地的趨勢的差異
  • 風險要素
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:多發性硬化症

  • 摘要整理
  • 產品概要
  • 附錄
  • 產品簡介:Ampyra
  • 產品簡介:Aubagio
  • 產品簡介:Avonex
  • 產品簡介:Betaseron
  • 產品簡介:Copaxone
  • 產品簡介:Extavia
  • 產品簡介:Gilenya
  • 產品簡介:Lemtrada
  • 產品簡介:Plegridy
  • 產品簡介:Rebif
  • 產品簡介:Tecfidera
  • 產品簡介:Tysabri

開發中產品:多發性硬化症

  • 摘要整理
  • 臨床實驗開發平台概要
  • 附錄
  • 產品簡介 (最後階段):Nerventra
  • 產品簡介 (最後階段):Zinbryta
  • 產品簡介 (最後階段):Ocrelizumab
  • 產品簡介 (最後階段):ozanimod
  • 產品簡介 (最後階段):ponesimod
  • 產品簡介 (最後階段):siponimod

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4810

DISEASE OVERVIEW:

Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, it is thought to involve genetic, environmental, and infectious disease components. Current therapies for MS largely fall into two categories: symptomatic and disease-modifying, and both are frequently used in combination with one another.

MARKET SNAPSHOT:

  • Ocrevus's peak sales estimate increases as early data suggest it is competing across a range of treatment settings.
  • Despite the approvals of newer, more efficacious therapies, Copaxone and interferon beta remain key components of treatment practices in MS.
  • An overall increase in diagnosed prevalent MS cases is expected, despite declines in markets experiencing negative population growth.
  • Exciting newcomer Ocrevus is gaining considerable traction in only its first year of commercial availability.
  • Celgene must balance ozanimod pricing to maximize MS opportunity while ensuring reimbursement in secondary indications.
  • Products targeting progressive disease types will have favorable reimbursement.

TABLE OF CONTENTS

FORECAST: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE (LATE STAGE): ALKS 8700
  • PRODUCT PROFILE: AUBAGIO
  • PRODUCT PROFILE: AVONEX
  • PRODUCT PROFILE: BETASERON
  • PRODUCT PROFILE: COPAXONE
  • PRODUCT PROFILE: GILENYA
  • PRODUCT PROFILE: LEMTRADA
  • PRODUCT PROFILE: MAVENCLAD
  • PRODUCT PROFILE: OCREVUS
  • PRODUCT PROFILE: PLEGRIDY
  • PRODUCT PROFILE: REBIF
  • PRODUCT PROFILE: TECFIDERA
  • PRODUCT PROFILE: TYSABRI
  • PRODUCT PROFILE: ZINBRYTA
  • PRODUCT PROFILE (LATE STAGE): OFATUMUMAB
  • PRODUCT PROFILE (LATE STAGE): OZANIMOD
  • PRODUCT PROFILE (LATE STAGE): PONESIMOD
  • PRODUCT PROFILE (LATE STAGE): SIPONIMOD
  • PRODUCT PROFILE (LATE STAGE): UBLITUXIMAB

TREATMENT: MULTIPLE SCLEROSIS (Published on 17 November 2017)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • UNMET NEEDS IN MULTIPLE SCLEROSIS

EPIDEMIOLOGY: MULTIPLE SCLEROSIS (Published on 09 August 2016)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • SOURCES AND METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • APPENDIX

MARKETED DRUGS: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: AUBAGIO
  • PRODUCT PROFILE: AVONEX
  • PRODUCT PROFILE: BETASERON
  • PRODUCT PROFILE: COPAXONE
  • PRODUCT PROFILE: GILENYA
  • PRODUCT PROFILE: LEMTRADA
  • PRODUCT PROFILE: MAVENCLAD
  • PRODUCT PROFILE: OCREVUS
  • PRODUCT PROFILE: PLEGRIDY
  • PRODUCT PROFILE: REBIF
  • PRODUCT PROFILE: TECFIDERA
  • PRODUCT PROFILE: TYSABRI
  • PRODUCT PROFILE: ZINBRYTA

MULTIPLE SCLEROSIS PRICING, REIMBURSEMENT, AND ACCESS (Published on 25 July 2017)

  • EXECUTIVE SUMMARY
  • REGULATORY LABELS
  • PAYER ARCHETYPES
  • ACCESS TO RECENTLY LAUNCHED AND PIPELINE PRODUCTS
  • CLINICAL TRIAL DESIGN AND EVIDENTIARY REQUIREMENTS
  • US PRICING
  • US REIMBURSEMENT
  • JAPAN
  • PRICING IN THE FIVE MAJOR EU MARKETS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • METHODOLOGY

PIPELINE: MULTIPLE SCLEROSIS (Published on 24 November 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): ALKS 8700
  • PRODUCT PROFILE (LATE STAGE): OFATUMUMAB
  • PRODUCT PROFILE (LATE STAGE): OZANIMOD
  • PRODUCT PROFILE (LATE STAGE): PONESIMOD
  • PRODUCT PROFILE (LATE STAGE): SIPONIMOD
  • PRODUCT PROFILE (LATE STAGE): UBLITUXIMAB

LIST OF FIGURES

  • Figure 1: Multiple sclerosis - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for multiple sclerosis
  • Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 5: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype, 2016-25
  • Figure 6: Methodology flow for Datamonitor Healthcare's multiple sclerosis forecast
  • Figure 7: Price sources and calculations, by country
  • Figure 8: ALKS 8700 for multiple sclerosis - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 10: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 12: Aubagio for multiple sclerosis - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 14: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 15: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 16: Avonex for multiple sclerosis - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 18: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 19: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 20: Betaseron for multiple sclerosis - SWOT analysis
  • Figure 21: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 22: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 23: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 24: Copaxone for multiple sclerosis - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 26: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 27: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 28: Gilenya for multiple sclerosis - SWOT analysis
  • Figure 29: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 30: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 31: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 32: Lemtrada for multiple sclerosis - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 34: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 35: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 36: Mavenclad for multiple sclerosis - SWOT analysis
  • Figure 37: Datamonitor Healthcare's drug assessment summary for Mavenclad in multiple sclerosis
  • Figure 38: Datamonitor Healthcare's drug assessment summary for cladribine in multiple sclerosis
  • Figure 39: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 40: Ocrevus for multiple sclerosis - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 42: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 43: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 44: Plegridy for multiple sclerosis - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 46: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 47: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 48: Rebif for multiple sclerosis - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 50: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 51: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 52: Tecfidera for multiple sclerosis - SWOT analysis
  • Figure 53: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 54: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 55: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 56: Tysabri for multiple sclerosis - SWOT analysis
  • Figure 57: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 58: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 59: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 60: Zinbryta for multiple sclerosis - SWOT analysis
  • Figure 61: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 62: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 63: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 64: Ofatumumab for multiple sclerosis - SWOT analysis
  • Figure 65: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 67: Ozanimod for multiple sclerosis - SWOT analysis
  • Figure 68: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 69: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 70: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 71: Ponesimod for multiple sclerosis - SWOT analysis
  • Figure 72: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 73: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 74: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 75: Siponimod for multiple sclerosis - SWOT analysis
  • Figure 76: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 78: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 79: Ublituximab for multiple sclerosis - SWOT analysis
  • Figure 80: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 81: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 82: Disability accumulation in the three main clinical subtypes of multiple sclerosis
  • Figure 83: Segmentation of respondents' multiple sclerosis patients in the US, Japan, and five major EU markets, by disease subtype, 2016
  • Figure 84: RRMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 85: PPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 86: SPMS patients who fall into each treatment category in the US, Japan, and five major EU markets, by country, 2016
  • Figure 87: Use of monotherapy or combination regimens of disease-modifying drugs, by disease subtype and line of therapy, 2016
  • Figure 88: Top five disease-modifying therapies used at first line in RRMS patients in the US, Japan, and five major EU markets, by country
  • Figure 89: Top five disease-modifying therapies used at second line and later in RRMS patients in the US, Japan, and five major EU markets, by country
  • Figure 90: Top five disease-modifying therapies used at first line in PPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 91: Top five disease-modifying therapies used at second line and later in PPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 92: Top five disease-modifying therapies used at first line in SPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 93: Top five disease-modifying therapies used at second line and later in SPMS patients in the US, Japan, and five major EU markets, by country
  • Figure 94: Average compliance rates with disease-modifying therapies, by disease subtype and drug administration route, 2016
  • Figure 95: Key unmet needs in multiple sclerosis across the US, Japan, and five major EU markets, 2016
  • Figure 96: Diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 97: Absolute change in diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Figure 98: Aubagio for multiple sclerosis - SWOT analysis
  • Figure 99: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 100: Datamonitor Healthcare's drug assessment summary for Aubagio in multiple sclerosis
  • Figure 101: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 102: Avonex for multiple sclerosis - SWOT analysis
  • Figure 103: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 104: Datamonitor Healthcare's drug assessment summary for Avonex in multiple sclerosis
  • Figure 105: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 106: Betaseron for multiple sclerosis - SWOT analysis
  • Figure 107: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 108: Datamonitor Healthcare's drug assessment summary for Betaseron in multiple sclerosis
  • Figure 109: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 110: Copaxone for multiple sclerosis - SWOT analysis
  • Figure 111: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 112: Datamonitor Healthcare's drug assessment summary for Copaxone in multiple sclerosis
  • Figure 113: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 114: Gilenya for multiple sclerosis - SWOT analysis
  • Figure 115: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 116: Datamonitor Healthcare's drug assessment summary for Gilenya in multiple sclerosis
  • Figure 117: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 118: Lemtrada for multiple sclerosis - SWOT analysis
  • Figure 119: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 120: Datamonitor Healthcare's drug assessment summary for Lemtrada in multiple sclerosis
  • Figure 121: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 122: Mavenclad for multiple sclerosis - SWOT analysis
  • Figure 123: Datamonitor Healthcare's drug assessment summary for Mavenclad in multiple sclerosis
  • Figure 124: Datamonitor Healthcare's drug assessment summary for cladribine in multiple sclerosis
  • Figure 125: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 126: Ocrevus for multiple sclerosis - SWOT analysis
  • Figure 127: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 128: Datamonitor Healthcare's drug assessment summary for Ocrevus in multiple sclerosis
  • Figure 129: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 130: Plegridy for multiple sclerosis - SWOT analysis
  • Figure 131: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 132: Datamonitor Healthcare's drug assessment summary for Plegridy in multiple sclerosis
  • Figure 133: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 134: Rebif for multiple sclerosis - SWOT analysis
  • Figure 135: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 136: Datamonitor Healthcare's drug assessment summary for Rebif in multiple sclerosis
  • Figure 137: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 138: Tecfidera for multiple sclerosis - SWOT analysis
  • Figure 139: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 140: Datamonitor Healthcare's drug assessment summary for Tecfidera in multiple sclerosis
  • Figure 141: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 142: Tysabri for multiple sclerosis - SWOT analysis
  • Figure 143: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 144: Datamonitor Healthcare's drug assessment summary for Tysabri in multiple sclerosis
  • Figure 145: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 146: Zinbryta for multiple sclerosis - SWOT analysis
  • Figure 147: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 148: Datamonitor Healthcare's drug assessment summary for Zinbryta in multiple sclerosis
  • Figure 149: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 150: ALKS 8700 for multiple sclerosis - SWOT analysis
  • Figure 151: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 152: Datamonitor Healthcare's drug assessment summary of ALKS 8700 for multiple sclerosis
  • Figure 153: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 154: Ofatumumab for multiple sclerosis - SWOT analysis
  • Figure 155: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 156: Datamonitor Healthcare's drug assessment summary of ofatumumab for multiple sclerosis
  • Figure 157: Ozanimod for multiple sclerosis - SWOT analysis
  • Figure 158: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 159: Datamonitor Healthcare's drug assessment summary of ozanimod for multiple sclerosis
  • Figure 160: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 161: Ponesimod for multiple sclerosis - SWOT analysis
  • Figure 162: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 163: Datamonitor Healthcare's drug assessment summary of ponesimod for multiple sclerosis
  • Figure 164: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country, 2016-25
  • Figure 165: Siponimod for multiple sclerosis - SWOT analysis
  • Figure 166: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 167: Datamonitor Healthcare's drug assessment summary of siponimod for multiple sclerosis
  • Figure 168: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 169: Ublituximab for multiple sclerosis - SWOT analysis
  • Figure 170: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis
  • Figure 171: Datamonitor Healthcare's drug assessment summary of ublituximab for multiple sclerosis

LIST OF TABLES

  • Table 1: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 2: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by formulation ($m), 2016-25
  • Table 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by disease subtype ($m), 2016-25
  • Table 4: Multiple sclerosis market treated patient numbers across the US, Japan, and five major EU markets, by disease subtype, 2016-25
  • Table 5: Sales of the top three highest selling drugs in multiple sclerosis in 2025 across the US, Japan, and five major EU markets ($m), 2016-25
  • Table 6: Summary of drug classes and molecules included in Datamonitor Healthcare's multiple sclerosis patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Neurologists surveyed for the multiple sclerosis primary research study, 2016
  • Table 9: ALKS 8700 drug profile
  • Table 10: ALKS 8700 Phase III trials in multiple sclerosis
  • Table 11: ALKS 8700 sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 12: Aubagio drug profile
  • Table 13: Aubagio pivotal trial data in multiple sclerosis
  • Table 14: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 15: Avonex drug profile
  • Table 16: Avonex pivotal trial data in multiple sclerosis
  • Table 17: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 18: Betaseron drug profile
  • Table 19: Betaseron pivotal trial data in multiple sclerosis
  • Table 20: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 21: Copaxone drug profile
  • Table 22: Copaxone pivotal trial data in multiple sclerosis
  • Table 23: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 24: Gilenya drug profile
  • Table 25: Gilenya pivotal trial data in multiple sclerosis
  • Table 26: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 27: Lemtrada drug profile
  • Table 28: Lemtrada pivotal trial data in multiple sclerosis
  • Table 29: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 30: Mavenclad drug profile
  • Table 31: Mavenclad pivotal trial data in multiple sclerosis
  • Table 32: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 33: Ocrevus drug profile
  • Table 34: Ocrevus pivotal trial data in multiple sclerosis
  • Table 35: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 36: Plegridy drug profile
  • Table 37: Plegridy pivotal trial data in multiple sclerosis
  • Table 38: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 39: Rebif drug profile
  • Table 40: Rebif pivotal trial data in multiple sclerosis
  • Table 41: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 42: Tecfidera drug profile
  • Table 43: Tecfidera pivotal trial data in multiple sclerosis
  • Table 44: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 45: Tysabri drug profile
  • Table 46: Tysabri pivotal trial data in multiple sclerosis
  • Table 47: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 48: Zinbryta drug profile
  • Table 49: Zinbryta pivotal trial data in multiple sclerosis
  • Table 50: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 51: Ofatumumab drug profile
  • Table 52: Ofatumumab Phase III trials in multiple sclerosis
  • Table 53: Ozanimod drug profile
  • Table 54: Ozanimod Phase III data in multiple sclerosis
  • Table 55: Ozanimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 56: Ponesimod drug profile
  • Table 57: Ponesimod Phase III trials in multiple sclerosis
  • Table 58: Ponesimod sales for multiple sclerosis across the US and five major EU markets, by country ($m), 2016-25
  • Table 59: Siponimod drug profile
  • Table 60: Siponimod Phase III data in multiple sclerosis
  • Table 61: Siponimod sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 62: Ublituximab drug profile
  • Table 63: Ublituximab Phase III trials in multiple sclerosis
  • Table 64: Neurologists surveyed for the multiple sclerosis primary research study, 2016
  • Table 65: Clinical subtypes of multiple sclerosis
  • Table 66: Multiple sclerosis diagnostic criteria
  • Table 67: Primary multiple sclerosis symptoms
  • Table 68: Leading disease-modifying therapies for multiple sclerosis
  • Table 69: Commonly used guidelines/consensus papers for the treatment of multiple sclerosis
  • Table 70: Multiple sclerosis patients treated with disease-modifying therapy in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 71: Prescription trends in first-line RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 72: Prescription trends in second-line and later RRMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 73: Prescription trends in first-line PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 74: Prescription trends in second-line and later PPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 75: Prescription trends in first-line SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 76: Prescription trends in second-line and later SPMS patients in the US, Japan, and five major EU markets, by country (%), 2016
  • Table 77: Mean compliance rates with oral disease-modifying therapies in the US, Japan, and five major EU markets, by disease subtype and country, 2016
  • Table 78: Mean compliance rates with subcutaneous, injectable disease-modifying therapies, by disease subtype and country, 2016
  • Table 79: Side effects demonstrated by current multiple sclerosis treatments
  • Table 80: Sources used for the epidemiological analysis of multiple sclerosis prevalence in the US, Japan, and five major EU markets
  • Table 81: Diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by country, 2015-35
  • Table 82: Age-specific diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by country, 2015
  • Table 83: Gender-specific diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by country, 2015
  • Table 84: Diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by subtype, 2015
  • Table 85: Diagnosed prevalent cases of multiple sclerosis in the US, Japan, and five major EU markets, by presenting symptoms, 2015
  • Table 86: Profiled key marketed drugs for multiple sclerosis
  • Table 87: Aubagio drug profile
  • Table 88: Aubagio pivotal trial data in multiple sclerosis
  • Table 89: Aubagio sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 90: Avonex drug profile
  • Table 91: Avonex pivotal trial data in multiple sclerosis
  • Table 92: Avonex sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 93: Betaseron drug profile
  • Table 94: Betaseron pivotal trial data in multiple sclerosis
  • Table 95: Betaseron sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 96: Copaxone drug profile
  • Table 97: Copaxone pivotal trial data in multiple sclerosis
  • Table 98: Copaxone sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 99: Gilenya drug profile
  • Table 100: Gilenya pivotal trial data in multiple sclerosis
  • Table 101: Gilenya sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 102: Lemtrada drug profile
  • Table 103: Lemtrada pivotal trial data in multiple sclerosis
  • Table 104: Lemtrada sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 105: Mavenclad drug profile
  • Table 106: Mavenclad pivotal trial data in multiple sclerosis
  • Table 107: Mavenclad sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 108: Ocrevus drug profile
  • Table 109: Ocrevus pivotal trial data in multiple sclerosis
  • Table 110: Ocrevus sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 111: Plegridy drug profile
  • Table 112: Plegridy pivotal trial data in multiple sclerosis
  • Table 113: Plegridy sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 114: Rebif drug profile
  • Table 115: Rebif pivotal trial data in multiple sclerosis
  • Table 116: Rebif sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 117: Tecfidera drug profile
  • Table 118: Tecfidera pivotal trial data in multiple sclerosis
  • Table 119: Tecfidera sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 120: Tysabri drug profile
  • Table 121: Tysabri pivotal trial data in multiple sclerosis
  • Table 122: Tysabri sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 123: Zinbryta drug profile
  • Table 124: Zinbryta pivotal trial data in multiple sclerosis
  • Table 125: Zinbryta sales for multiple sclerosis across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 126: Marketed products and approved indications for multiple sclerosis in the US, Japan, and five major EU markets
  • Table 127: Levers impacting access to multiple sclerosis drugs in the US and five major EU markets
  • Table 128: US pricing of key marketed drugs, 2017
  • Table 129: Top multiple sclerosis drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2015
  • Table 130: Multiple sclerosis spend by payers, 2016
  • Table 131: Specialty drug spend by Express Scripts members, by payer type (multiple sclerosis market), 2016
  • Table 132: CVS Caremark's and Express Scripts' formulary exclusions for multiple sclerosis drugs
  • Table 133: Formulary placement of multiple sclerosis medications in selected commercial formularies
  • Table 134: Formulary placement of multiple sclerosis medications in selected Medicare formularies
  • Table 135: Formulary placement of multiple sclerosis medications, by region
  • Table 136: Prior authorization criteria for multiple sclerosis drugs in major health insurers and PBMs
  • Table 137: Multiple sclerosis drug pricing compared to ICER value-price benchmarks
  • Table 138: Japan - pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 139: Price calculation methodologies for multiple sclerosis drugs in Japan launched after 2008
  • Table 140: Pricing of key marketed multiple sclerosis drugs in Japan, 2016
  • Table 141: Pricing of key multiple sclerosis drugs in the five major EU markets, by country, 2016
  • Table 142: Transparency Committee's ASMR ratings and pricing implications
  • Table 143: Transparency Committee's SMR ratings and pricing implications
  • Table 144: Transparency Commission's assessment of multiple sclerosis treatments
  • Table 145: G-BA assessment of key multiple sclerosis therapies
  • Table 146: EMA labels and G-BA assessments for Gilenya
  • Table 147: Reimbursement conditions for multiple sclerosis treatments in Italy
  • Table 148: Italian regional formulary decisions for multiple sclerosis drugs
  • Table 149: Therapeutic positioning reports for multiple sclerosis drugs in Spain
  • Table 150: Spanish Society of Hospital Pharmacy ratings
  • Table 151: Regional MADRE assessments for multiple sclerosis drugs
  • Table 152: NICE assessments of key multiple sclerosis therapies
  • Table 153: UK regional formulary decisions for multiple sclerosis drugs, 2017
  • Table 154: SMC decisions on key multiple sclerosis therapies
  • Table 155: Price sources and calculations for the US
  • Table 156: Price sources and calculations for the EU
Back to Top